NCT00158782 2017-11-17
Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients
GlaxoSmithKline
Phase 1 Completed
GlaxoSmithKline
GlaxoSmithKline
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC
National Cancer Institute (NCI)
University of Michigan Rogel Cancer Center
University Hospital, Bordeaux
GlaxoSmithKline